S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis

Table 1 Baseline characteristics

Study	Year	Country	Number of patients		Treatments
			S-1	non-S-1	Experimental arm	Control arm
Ajani et al[24]	2013	Non-Asian	521	508	S-1: 25 mg/m2, B.i.d, day 1-21; cisplatin: 75 mg/m2, civ 1-3 h, day 1, q.4.w.	5-FU: 1000 mg/m2/24 h, day 1-5; cisplatin: 100 mg/m2, civ 1-3 h, q.4.w.
Huang et al[25]	2013	China	119	110	S-1: 80-120 mg/d, day 1-14; paclitaxel: 60 mg/m2, iv, day 1, 8 and 15, q.4.w.	5-FU: 500 mg/m2, civ, day 1-5; leucovorin 20 mg/m2, iv, day 1-5; paclitaxel: 60 mg/m2, iv, day 1, 8 and 15, q.4.w.
Kim et al[26]	2012	Korea	65	64	S-1: 80 mg/d, day 1-14; Oxaliplatin: 130 mg/m2, iv (2 h), day 1, q.3.w.	Capecitabine: 2000 mg/d, day 1-14; Oxaliplatin: 130 mg/m2, iv (2 h), day 1, q.3.w.
Nishikawa et al[27]	2012	Japan	80	77	(sequential), S-1: 80 mg/m2, day 1-28, 2-wk rest followed by PTX; or (concurrent), S-1: 14 d and PTX: 50 mg/m2, day 1, 8, q.3.w.	(sequential), intravenous 5-FU: 800 mg/m2, iv, day 1-5, followed by weekly PTX at 80 mg/m2; or (concurrent), 5-FU: 600 mg/m2, iv, day 1-5 and weekly PTX at 80 mg/m2, q.4.w.
Jeung et al[20]	2010	Korea	37	38	S-1: 35 mg/m2, B.i.d, day 1-14; doc: 35 mg/m2, day 1, 8, q.3.w.	cisplatin: 35 mg/m2, day 1, 8; doc: 35 mg/m2, day 1, 8, q.3.w.
Boku et al[22]	2009	Japan	234	232	S-1: 40 mg/m2, B.i.d, day 1-28, q.6.w.	5-FU: 800 mg/m2, civ, day 1-5, q.4.w.
Lee et al[23]	2008	Korea	45	46	S-1: 40 mg/m2 (BSA < 1.25 m2), 50 mg/m2 (BSA: 1.25-1.5 m2), 60 mg/m2 (BSA > 1.5 m2), B.i.d, day 1-28, q.6.w.	Capecitabine: 1250 mg/m2, B.i.d, day 1-14, q.3.w.

5-FU: 5-fluorouracil; PTX: Paclitaxel; BSA: Body surface area.